Core Viewpoint - Co-Diagnostics, Inc. has entered a joint venture with Arabian Eagle Manufacturing in Saudi Arabia to develop and commercialize its diagnostic technologies across the Middle East and North Africa, aligning with Saudi Vision 2030 [1][3]. Group 1: Joint Venture Details - The joint venture will focus on research, development, manufacturing, assembly, distribution, and commercialization of Co-Dx technologies, including the upcoming Co-Dx PCR point-of-care platform [1][3]. - Financial terms of the joint venture were not disclosed [2]. - Arabian Eagle will manage local operational support, setup of the manufacturing facility, regulatory clearance, and compliance [5]. Group 2: Strategic Alignment and Market Potential - The partnership supports key pillars of Saudi Vision 2030, emphasizing technology localization, industrial diversification, and healthcare innovation [3]. - The KSA is identified as having a large and growing market for medical devices and point-of-care diagnostics, with demand drivers published by the government [5]. Group 3: Product Development and Clinical Evaluation - The new platform will include tests for infectious diseases such as tuberculosis, an 8-type HPV multiplex test, and a respiratory multiplex test for influenza A and B, COVID-19, and RSV, with clinical evaluations expected to begin before the end of 2025 [7]. - Co-Diagnostics will provide Arabian Eagle an exclusive license to use, manufacture, and commercialize its intellectual property, including the upcoming Co-Dx PCR platform and existing lab-based PCR diagnostic products [6].